(ALGS) Aligos Therapeutics - Ratings and Ratios

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is pioneering the development of novel therapeutics to tackle unmet medical needs in viral and liver diseases, with a robust pipeline of drug candidates in various stages of clinical trials.

The companys lead drug candidate, ALG-055009, is a small molecule THR-ß agonist that has entered Phase 2a clinical trials for the treatment of non-alcoholic steatohepatitis (NASH), a condition with a growing demand for effective treatments. Additionally, Aligos is advancing ALG-000184, a capsid assembly modulator that has completed Phase 1b clinical trials for the treatment of chronic hepatitis B (CHB), and ALG-125755, a siRNA drug candidate in Phase I clinical trials for CHB treatment.

Aligos is also making strides in developing treatments for coronavirus with ALG-097558, which is currently in Phase 2 clinical trials. The companys partnerships with renowned institutions, such as Merck, Emory University, Luxna Biotech Co., Ltd., and Katholieke Universiteit Leuven, underscore its commitment to leveraging cutting-edge research and technology to drive innovation.

Analyzing the , the stocks current price is $6.06, with a 20-day SMA of $5.43, indicating a potential bullish trend. However, the 50-day SMA of $6.91 and 200-day SMA of $16.25 suggest a longer-term downtrend. The ATR of 0.72 (11.89% volatility) implies a relatively high level of price fluctuation. Considering the , the companys market capitalization is $35.71M USD, with a negative P/E ratio and RoE of -104.02, indicating significant losses.

Based on the available data, a forecast for ALGS can be constructed. Given the current price and SMA trends, a potential short-term target could be $7.00, representing a 15% increase from the current price. However, the long-term downtrend and high volatility suggest that investors should exercise caution. If the companys pipeline continues to progress and partnerships yield positive results, a potential long-term target could be $20.00, representing a 230% increase from the current price. Nevertheless, the negative fundamental data and high volatility make this a high-risk investment.